These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 37627175)

  • 41. Non-small-cell lung cancer: how to manage
    Andrini E; Mosca M; Galvani L; Sperandi F; Ricciuti B; Metro G; Lamberti G
    Drugs Context; 2022; 11():. PubMed ID: 35912003
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The return of RET GateKeeper mutations? an in-silico exploratory analysis of potential resistance mechanisms to novel RET macrocyclic inhibitor TPX-0046.
    Repetto M; Crimini E; Ascione L; Boscolo Bielo L; Belli C; Curigliano G
    Invest New Drugs; 2022 Oct; 40(5):1133-1136. PubMed ID: 35612671
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A Performance Comparison of Commonly Used Assays to Detect RET Fusions.
    Yang SR; Aypar U; Rosen EY; Mata DA; Benayed R; Mullaney K; Jayakumaran G; Zhang Y; Frosina D; Drilon A; Ladanyi M; Jungbluth AA; Rekhtman N; Hechtman JF
    Clin Cancer Res; 2021 Mar; 27(5):1316-1328. PubMed ID: 33272981
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Adaptive Darwinian off-target resistance mechanisms to selective RET inhibition in RET driven cancer.
    Subbiah V; Gouda MA; Iorgulescu JB; Dadu R; Patel K; Sherman S; Cabanillas M; Hu M; Castellanos LE; Amini B; Meric-Bernstam F; Shen T; Wu J
    NPJ Precis Oncol; 2024 Mar; 8(1):62. PubMed ID: 38438731
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Therapeutic Advances in the Management of Patients with Advanced RET Fusion-Positive Non-Small Cell Lung Cancer.
    Sun F; McCoach CE
    Curr Treat Options Oncol; 2021 Jun; 22(8):72. PubMed ID: 34165651
    [TBL] [Abstract][Full Text] [Related]  

  • 46. RET rearrangements in non-small cell lung cancer: Evolving treatment landscape and future challenges.
    Servetto A; Esposito D; Ferrara R; Signorelli D; Belli S; Napolitano F; Santaniello A; Ciciola P; Formisano L; Bianco R
    Biochim Biophys Acta Rev Cancer; 2022 Nov; 1877(6):188810. PubMed ID: 36202311
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pralsetinib treatment for multiple
    Cao X; Liu X; Wang S; Liu Z; Ren X; Sun D; Deng L
    J Int Med Res; 2022 Jun; 50(6):3000605221105368. PubMed ID: 35751411
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Case report: First evidence of impressive efficacy of modulated dose selpercatinib in a young Caucasian with ANK3-RET fusion-positive NSCLC.
    De Carlo E; Bertoli E; Schiappacassi M; Stanzione B; Del Conte A; Doliana R; Spina M; Bearz A
    Front Oncol; 2024; 14():1307458. PubMed ID: 38420011
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Selpercatinib for adult patients with locally advanced or metastatic RET-altered solid tumors.
    Le D; Konda B
    Expert Rev Anticancer Ther; 2023; 23(11):1117-1122. PubMed ID: 37795873
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Clinical evidence and adverse event management update of patients with RET- rearranged advanced non-small-cell lung cancer (NSCLC) treated with pralsetinib.
    Russo GL; Bironzo P; Bennati C; Bonanno L; Catino A; Metro G; Petrini I; Russano M; Passaro A
    Crit Rev Oncol Hematol; 2024 Feb; 194():104243. PubMed ID: 38135019
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pralsetinib in RET fusion-positive non-small-cell lung cancer: A real-world data (RWD) analysis from the Italian expanded access program (EAP).
    Passaro A; Russo GL; Passiglia F; D'Arcangelo M; Sbrana A; Russano M; Bonanno L; Giusti R; Metro G; Bertolini F; Grisanti S; Carta A; Cecere F; Montrone M; Massa G; Perrone F; Simionato F; Guaitoli G; Scotti V; Genova C; Lugini A; Bonomi L; Attili I; de Marinis F
    Lung Cancer; 2022 Dec; 174():118-124. PubMed ID: 36379124
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Tumor-Type Agnostic, Targeted Therapies: BRAF Inhibitors Join the Group.
    Vranic S; Basu GD; Hall DW; Gatalica Z
    Acta Med Acad; 2022 Dec; 51(3):217-231. PubMed ID: 36799315
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The L730V/I RET roof mutations display different activities toward pralsetinib and selpercatinib.
    Shen T; Hu X; Liu X; Subbiah V; Mooers BHM; Wu J
    NPJ Precis Oncol; 2021 Jun; 5(1):48. PubMed ID: 34099825
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A comprehensive overview of the relationship between RET gene and tumor occurrence.
    Zhao L; Wang N; Zhang D; Jia Y; Kong F
    Front Oncol; 2023; 13():1090757. PubMed ID: 36865807
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Current perspectives on the management of patients with advanced
    Elisei R; Grande E; Kreissl MC; Leboulleux S; Puri T; Fasnacht N; Capdevila J
    Front Oncol; 2023; 13():1141314. PubMed ID: 37207147
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Integrated budget impact model to estimate the impact of introducing selpercatinib as a tumor-agnostic treatment option for patients with
    Bhandari NR; Gilligan AM; Myers J; Ale-Ali A; Smolen L
    J Med Econ; 2024; 27(1):348-358. PubMed ID: 38334069
    [TBL] [Abstract][Full Text] [Related]  

  • 57. FDA Approval Summary: Pralsetinib for the Treatment of Lung and Thyroid Cancers With
    Kim J; Bradford D; Larkins E; Pai-Scherf LH; Chatterjee S; Mishra-Kalyani PS; Wearne E; Helms WS; Ayyoub A; Bi Y; Sun J; Charlab R; Liu J; Zhao H; Liang D; Ghosh S; Philip R; Pazdur R; Theoret MR; Beaver JA; Singh H
    Clin Cancer Res; 2021 Oct; 27(20):5452-5456. PubMed ID: 34045295
    [TBL] [Abstract][Full Text] [Related]  

  • 58. ESMO recommendations on the standard methods to detect RET fusions and mutations in daily practice and clinical research.
    Belli C; Penault-Llorca F; Ladanyi M; Normanno N; Scoazec JY; Lacroix L; Reis-Filho JS; Subbiah V; Gainor JF; Endris V; Repetto M; Drilon A; Scarpa A; André F; Douillard JY; Curigliano G
    Ann Oncol; 2021 Mar; 32(3):337-350. PubMed ID: 33455880
    [TBL] [Abstract][Full Text] [Related]  

  • 59. FDA Approval Summary: Selpercatinib for the Treatment of Lung and Thyroid Cancers with
    Bradford D; Larkins E; Mushti SL; Rodriguez L; Skinner AM; Helms WS; Price LSL; Zirkelbach JF; Li Y; Liu J; Charlab R; Turcu FR; Liang D; Ghosh S; Roscoe D; Philip R; Zack-Taylor A; Tang S; Kluetz PG; Beaver JA; Pazdur R; Theoret MR; Singh H
    Clin Cancer Res; 2021 Apr; 27(8):2130-2135. PubMed ID: 33239432
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Case report: identification of
    Ma J; Wang B; Meng E; Meng X
    Gland Surg; 2021 Sep; 10(9):2874-2879. PubMed ID: 34733735
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.